Journal article
Gene delivery of calreticulin anti-angiogenic domain attenuates the development of choroidal neovascularization in rats
YS Bee, L Tu, SJ Sheu, HC Lin, JH Tang, JH Wang, SM Prea, GJ Dusting, DC Wu, J Zhong, BV Bui, MH Tai, GS Liu
Human Gene Therapy | MARY ANN LIEBERT, INC | Published : 2017
DOI: 10.1089/hum.2016.035
Abstract
Choroidal neovascularization (CNV) is a common pathological feature in neovascular age-related macular degeneration, which is the leading cause of vision loss among elderly populations in developed countries. This study evaluated the effect of a novel endogenous inhibitor of angiogenesis, calreticulin anti-angiogenic domain (CAD), subconjunctivally delivered by an adenoviral vector (Ad-CAD) in a rat model of laser-induced CNV. CAD was expressed in Ad-CAD-infected cells and inhibited the angiogenic activity in human umbilical vein endothelial cells in vitro. CAD expression was also found in various ocular tissues after in vivo subconjunctival Ad-CAD injection. Via bioluminescence imaging it i..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This work was supported by grants from Kaohsiung Veterans General Hospital (VGHKS 97-106, 98-062, 99-062, and 100-066), Kaohsiung Medical University (KMU-TP104G00, KMU-TP104G03 and KMU-TP104G04), NSYSU-MKU Joint Project (102-P035), the Ministry of Science and Technology of Taiwan (MOST 103-2325-B-110-002), and the National Health and Medical Research Council of Australia (NHMRC#1061912), the Ophthalmic Research Institute of Australia, and the Angior Family Foundation. G.J.D. receives a Principal Research Fellowship from NHMRC. The Centre for Eye Research Australia receives Operational Infrastructure Support from the Victorian Government.